You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 5,227,157

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,227,157

Title:	Delivery of therapeutic agents
Abstract:	The present invention relates to a composition of matter for the time-dependent liberation of therapeutic agents. This composition of matter comprises a polymeric slab and a homogeneously dispersed enzyme which degrades the polymeric slab in the presence of moisture. The therapeutic agent is physically entrapped in the polymeric slab by inclusion during polymerization to form the polymeric slab or by mixture of the therapeutic agent with a liquid form of the polymeric slab and conversion of the liquid to a solid form. The therapeutic agent is not chemically bound to the polymer, and thus release of the agent is immediately effected upon the specific moisture-activated enzymatic degradation of the polymer slab. Moisture for enzymatic activation is provided by the biological surface on which the slab is emplaced, such as the dermal surface. The composition comprises a polymer such as poly (DL-lactide) and an enzyme such as proteinase K together with chlorpheniramine maleate as the therapeutic agent.
Inventor(s):	McGinity; James W. (Austin, TX), Ashley; Susan L. (Overland Park, KS)
Assignee:	Board of Regents, The University of Texas System (Austin, TX)
Application Number:	07/388,321
Patent Claims:	1. A pharmacologically acceptable composition of matter comprising: a biodegradable polymeric slab; a moisture activated enzyme included within the polymeric slab in a therapeutic agent releasing concentration which enzymatically degrades said slab; a non-polymer bound therapeutic agent incorporated into said slab, wherein enzymatic degradation of the biodegradable polymeric slab releases the incorporated therapeutic agent at a rate which is a function of the concentration of the enzyme in the slab. 2. A pharmacologically acceptable composition of matter for the time dependent liberation of a therapeutic agent in vivo, the composition consisting essentially of: a biologically degradable polymeric slab; a non-polymer bound, homogeneously dispersed therapeutic agent physically entrapped in said polymeric slab; and an enzyme included at a concentration within the polymeric slab which degrades said slab in the presence of moisture to facilitate the controlled release of entrapped therapeutic agent at a rate which is a function of the concentration of the enzyme in the slab. 3. A deliver device for the transdermal administration of a therapeutic agent, said device comprising: a polymeric slab having a side for dermal contact; a non-polymer bound, homogeneously dispersed therapeutic agent physically entrapped in said polymeric slab; at least one moisture activated enzyme included within the slab at a concentration which provides for the controlled release of the therapeutic agent; and a means for holding the device in dermal contact, wherein the therapeutic agent is released at a rate which is a function of the concentration of the enzyme within the slab. 4. The composition of claim 1 or 2 or delivery device of claim 3 wherein the polymeric slab comprises a polymer selected from the group consisting of: polyesters, polyamides, polypeptides, polysaccharides, cellulose, dextran, elastin, fibrin, gelatin, polyethylene, pectin, and polygalacturonic acid. 5. The composition of claim 1 or 2 or delivery device of claim 3 wherein the polymeric slab comprises a biodegradable polyester. 6. The composition of claim 1 or 2 delivery device of claim 3 wherein the polymeric slab comprises a polyester of biologically metabolizable monomeric units selected from the group consisting of lactic acid, glycolic acid, hydroxypropionic acid, and hydroxybutyric acid. 7. The composition of claim 1 or 2 or delivery device of claim 3 wherein the polymeric slab comprises a polyester of biologically metabolizable monomeric units of lactic acid or glycolic acid. 8. The composition of claim 1 or 2 or delivery device of claim 3 wherein the polymeric slab comprises a polyamide. 9. A composition of claim 1 or 2 or delivery device of claim 3 wherein the polymeric slab comprises a polypeptide. 10. The composition of claim 1 or 2 or delivery device of claim 3 wherein the enzyme hydrolyses ester bonds and comprises a hydrolase or a protease. 11. The composition of claim 1 or 2 or delivery device of claim 3 wherein the enzyme is selected from the group consisting of: proteinase K, bromelain, pronase E, cellulase, dextranase, elastase, plasmid, streptokinase, trypsin, chymotrypsin, papain, chymopapain, collagenase, subtilisin, ficin, carboxypeptidase A, pectinase, and pectinesterase. 12. The composition of claims 1 or 2 or delivery device of claim 3 wherein the enzyme is proteinase K, bromelain or pronase E. 13. The compositions of claim 1 or 2 or delivery device of claim 3 wherein the enzyme is proteinase K. 14. The compositions of claim 1 or 2 or delivery device of claim 3 wherein the enzyme is proteinase K at a concentration of about 0.5% by weight of the polymeric slab. 15. The device of claim 3 wherein the enzyme is dispersed on the side of the polymeric slab for contact with the dermal surface. 16. The delivery device of claim 3 wherein the means for holding the device in contact with a dermal surface is an adhesive, elastic band or bandaging tape. 17. The compositions of claim 1 or 2 or delivery device of claim 3 wherein the therapeutic agent comprises chlorpheniramine maleate. 18. A delivery device for the transdermal administration of a therapeutic agent, said device comprising: a poly(DL-lactide) polymeric slab having a side for dermal contact; a non-polymer bound, homogeneously dispersed therapeutic agent physically entrapped in said poly(DL-lactide) polymeric slab; proteinase K included with the slab, which degrades the polymeric slab in the presence of moisture to release the therapeutic agent; and a means for holding the device in dermal contact selected from the group consisting of: an adhesive; an elastic band; and a bandaging tape, wherein the therapeutic agent is released at a rate which is a function of the concentration of the enzyme within the slab.

Details for Patent 5,227,157

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	11/10/1982	⤷ Try a Trial	2010-07-13
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	08/21/1984	⤷ Try a Trial	2010-07-13
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2010-07-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.